Ascendis Pharma A (ASND) Retained Earnings (2012 - 2017)

Ascendis Pharma A has disclosed Retained Earnings across 6 years of filings, most recently posting $208.3 million for Q3 2017.

• Retained Earnings for Q3 2017 came in at $208.3 million, up 211.87% year-over-year; the trailing twelve-month figure through Sep 2017 was $208.3 million (up 211.87% YoY), and the FY2016 annual result was $172.0 million, up 2.68% from the prior year.
• Retained Earnings came in at $208.3 million for Q3 2017 at Ascendis Pharma A, up from $114.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $208.3 million in Q3 2017 to a low of $3.7 million in Q4 2013.
• The 5-year median for Retained Earnings is $137.1 million (2015), against an average of $120.8 million.
• Across the five-year window, Retained Earnings surged 1730.21% in 2014 and sank 51.28% in 2016, its largest moves.
• Ascendis Pharma A's Retained Earnings stood at $3.7 million in 2013, then soared by 1730.21% to $67.8 million in 2014, then surged by 146.87% to $167.5 million in 2015, then increased by 2.68% to $172.0 million in 2016, then grew by 21.16% to $208.3 million in 2017.
• The last three Retained Earnings figures came in at $208.3 million (Q3 2017), $114.4 million (Q2 2017), and $143.6 million (Q1 2017), per Business Quant data.